Skip to content
Rio de Janeiro · São Paulo · Salvador — matters across Brazil
Bruno Marcelos — Escritório de Advocacia

Pauta Regulatória · Daily brief

No. 30

Automatically translated from the Portuguese edition, which prevails in case of discrepancy. Ler em português

Federal Official Gazette

No updates.

ANS news

The ANS website was updated yesterday with four interviews given by president Wadih Damous to O Globo, Folha de São Paulo, Estado de São Paulo, Jota and Globonews.

Nov 11, 2025 – At a meeting at the Agency’s headquarters, it was determined that Unimed do Brasil will take over Unimed Ferj

Nov 11, 2025 – ANS Chief Executive Officer advocates “two-way” regulation and highlights the need to balance the interests of health plan operators and consumers

Nov 11, 2025 – Wadih Damous stated that regulation will be stricter in order to protect beneficiaries and prevent illegal practices in the sector

Nov 11, 2025 – Wadih Damous considered it unlikely that the new text of the Health Plans Bill (PL) will be brought to a vote this year

Nov 11, 2025 – Wadih Damous spoke about health plan price adjustments, collective contracts entered into by legal entities and strategic planning

Open public consultations

  • CP 163. Its purpose is to receive input on the proposals to update the List of Health Procedures and Events (Rol), more specifically on the preliminary recommendation against incorporation of the technologies covered by UAT No. 171 – Inclisiran, UAT No. 175 – Lebrikizumab and UAT No. 176 – Momelotinib. Deadline: Nov 5, 2025 to Nov 24, 2025

Scheduled public hearings

  • Public Hearing No. 61, Collection of input on the preliminary recommendation against incorporation of the following technologies:
    (i) UAT 171 – Inclisiran for the treatment of primary hypercholesterolemia or mixed dyslipidemia;
    (ii) UAT 175 – Lebrikizumab for the treatment of adult patients with severe atopic dermatitis who have failed, are intolerant to or have a contraindication to cyclosporine; and
    (iii) UAT 176 – Momelotinib for the treatment of intermediate- and high-risk myelofibrosis.

Date: November 19, 2025, from 9 a.m. to 1 p.m.

Open public calls for input

There are no open public calls for input.

Open public calls

No updates.

Other news

Unimed Brasil will receive 90% of the monthly fees of Unimed Ferj beneficiaries

Source: extra.globo.com · read the full article

Qualified inertia causes operator to lose right to adjusted monthly fees

Source: conjur.com.br · read the full article

DF: health plan is target of operation against laundering of R$ 26 million. Watch video

Source: metropoles.com · read the full article

Some beneficiaries do not recognize fraud against health plans, survey shows

Source: oglobo.globo.com · read the full article

Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.